While excellent outcomes of stereotactic body radiation therapy (SBRT) have been reported since it was first used to treat prostate cancer in 2003, the delivered doses have ranged from 35 Gy in five treatments to 40 Gy in five treatments. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: body, dose, optimal, radiation, SBRT, stereotactic | 6 Comments »
A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CT, free, gallium-68, PET, PSMA-11, radiation, salvage, scan, SRT, therapy | 4 Comments »
Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: dMMR, genotype, Management, MSI-H, phenotype, prevalence, rare, risk | 1 Comment »
An obvious but previously unanswered question has been whether adding data from the results of MRI scans to the data used in the Partin tables and in the pre-surgical Kattan nomogram (also known as the Memorial-Sloan Kettering Cancer Center or MSKCC nomogram) can improve the accuracy of these two commonly used prognostic methods. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Kattan, MRI. mpMRI, MSKCC, multiparametric, nomogram, Partin, prognosis, risk, score | 3 Comments »
For many years now, there have been subsets of specialists and patients who have argued that the “standard” serum testosterone level of 50 ng/dl, used by regulatory authorities and others as a measure indicating a castrate level of serum testosterone, is too high. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castrate, dhydrotestosterone, estosterone, level, serum | 18 Comments »
A newly published study in Urologic Oncology has reported data from a survey carried out by researchers at the National Cancer Institute into “the current practice patterns and views among urologists regarding focal therapy for prostate cancer”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: attitude, belief, focal, therapy, use | 2 Comments »
